S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Taysha Gene Therapies Shares Slide on $200 Million Stock Offering

A 9.8% drop in premarket trading greeted Taysha Gene Therapies on Thursday after the biotechnology firm finalized the pricing for a $200 million public offering. The company is diluting its existing equity base to raise capital, selling 32.5 million common shares at $6 apiece to bolster its financial runway.

Taysha Gene Therapies Shares Slide on $200 Million Stock Offering

The offering also includes pre-funded warrants for 833,333 shares, priced at the same $6 rate for investors opting out of immediate common stock ownership. To manage the sale, the company tapped a syndicate of heavyweights, including Jefferies, Goldman Sachs, Piper Sandler, and Cantor, to serve as joint book-running managers. The deal is slated to close on or about Friday.

Despite the immediate market reaction, the company remains in a strong position relative to its recent performance. Before this morning's slide to $6.26, the stock had climbed approximately 25% since the start of the year. Underwriters maintain a 30-day window to purchase an additional 5 million shares, a provision that could further adjust the total capital raised depending on market appetite.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!